Objective To develop a new evidence‐based, pharmacologic treatment guideline for
rheumatoid arthritis (RA). Methods We conducted systematic reviews to synthesize the …

Hepatitis B reactivation associated with immune-suppressive and biological therapies is
emerging to be an important cause of morbidity and mortality in patients with current or prior …

Conclusions HBsAg‐positive patients with HCC are at high or intermediate risk of HBV
reactivation depending on the type of HCC therapy. Nucleos (t) ide analogue prophylaxis …

Purpose To provide guidelines on antimicrobial prophylaxis for adult neutropenic oncology
outpatients and on selection and treatment as outpatients of those with fever and …

These guidelines have been written to assist physicians and other health care providers in
the recognition, diagnosis, and management of patients chronically infected with the …

More effective and less resistance-prone antiviral agents are now available to treat hepatitis
B virus (HBV) infection. Profound, durable, therapeutic HBV DNA suppression to slow and …

Diseases (AASLD) also presented and continued to revise their clinical practice guidelines,
and the latest updates were in 2015, 2017, and 2018. However, since the medical …

Occult hepatitis B virus (HBV) infection is one of the most challenging topics in the field of
viral hepatitis with its virological and clinical relevance being debated for more than 30 …

Serologic testing for hepatitis B surface antigen (HBsAg) is the primary way to identify
persons with chronic hepatitis B virus (HBV) infection. Testing has been recommended …

Purpose The role of antiviral prophylaxis in preventing hepatitis B virus (HBV) reactivation
before rituximab-based chemotherapy in patients with lymphoma and resolved hepatitis B is …